10-Q quarterly report · filed Nov 2, 2026

Bioventus Inc. (BVS) Q3 2026 10-Q Quarterly Report

Short answer

Bioventus Inc. (BVS) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $142M (up 2.7% year over year) with net income of $6M.

Q3 2026 key financials · XBRL

Revenue
$142M
+2.7% YoY · −7.0% QoQ
Net income
$6M
+89.8% YoY · −82.1% QoQ
Operating margin
6.8%
Gross margin
68.2%
EPS (diluted)
$0.08
+60.0% YoY · −83.3% QoQ

Source: XBRL data from the Bioventus Inc. (BVS) Q3 2026 10-Q on SEC EDGAR. USD.

Bioventus Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $142.4M, up $3.8M or 2.7% YoY
  • Operating margin 6.8% vs 8.1% YoY, net income $6.9M vs $4.0M
  • Best segment: International Surgical Solutions, sales $6.8M, up 31.0% YoY
  • Worst segment: International Restorative Therapies, sales $2.6M, down 10.5% YoY
  • Operating cash flow $49.5M, up $12.8M; debt repayments $64.5M and cash $30.7M vs $51.2M at year-end

Risk Factors

  • No material risk-factor changes from the 2025 10-K and June 27, 2026 Form 10-Q
  • Carried-forward business risks could materially affect financial condition or future results
  • Unknown or currently immaterial risks may adversely affect business performance

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Bioventus Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.